The New ADHD Drug That Targets Three Brain Chemicals, Not Two
The New ADHD Drug That Targets Three Brain Chemicals, Not Two
Imagine sending a text message and then immediately deleting it before the other person has a chance to read it. Thats essentially what happens in the brain when neurotransmitters like dopamine and norepinephrine send signals between brain cells—they get whisked away almost as soon as they arrive. For people with ADHD, this rapid cleanup process can make it harder to maintain attention, control impulses, and stay motivated.
Now, theres a new medication in the ADHD treatment toolbox that works a little differently. Its called centanafadine, sold under the brand name Simtriyo, and its the first ADHD drug designed to affect three brain chemicals instead of the usual two. The U.S. Food and Drug Administration has approved it for adults and children ages 6 and older. Its not yet available in Australia, but its already sparking interest among clinicians and patients alike.
So what makes this drug different? And does it actually matter for people living with ADHD?
A Different Approach to Brain Chemistry
Centanafadine belongs to a new class of ADHD medicines. Most existing ADHD drugs—stimulants like dexamfetamine, lisdexamfetamine, and methylphenidate—primarily boost two neurotransmitters: dopamine and norepinephrine. These chemicals are involved in attention, motivation, and self-control. Centanafadine does that too, but it also affects serotonin, which helps regulate mood, sleep, and appetite.
How does it work? Brain cells use neurotransmitters to send messages to each other. After a message is sent, the brain cell usually takes the chemical back up—a process called reuptake. Think of it as the brains way of cleaning up after a conversation. Centanafadine slows down that cleanup process, leaving more dopamine, norepinephrine, and serotonin available for longer. The result, in theory, is better communication between brain cells and potentially fewer ADHD symptoms.
Stimulant or Not? The Debate Continues
Heres where things get a little murky. Centanafadine affects the brain in ways that look similar to stimulants, but the pharmaceutical company that developed it called it a non-stimulant back in 2017. The FDA, however, refers to it as a stimulant in its product information. So which is it?
The distinction matters because stimulants are controlled substances with specific prescribing rules and potential for misuse. But for patients, the more important question is whether the drug works—and whether it offers something new.
Having another option is useful because not everyone responds to ADHD medications in the same way. Some people dont tolerate stimulants well. Others find that existing non-stimulants, like atomoxetine (Strattera), dont do enough for their symptoms. Centanafadine sits somewhere in between, affecting all three neurotransmitters rather than just one or two.
Its not an antidepressant, though. While it does affect serotonin, most antidepressants primarily target serotonin and norepinephrine, with less impact on dopamine. Centanafadines broader effect on dopamine is what makes it potentially useful for ADHD, where dopamine reward pathways play a key role.
What the Research Shows
Centanafadine was tested in four large phase 3 clinical trials before receiving FDA approval. These studies found that people taking the medication had improved ADHD symptoms, and it was generally well tolerated. One study in teenagers found symptoms improved within about a week.
But theres a catch. These trials compared centanafadine to a placebo, not to existing ADHD medications like methylphenidate or dexamfetamine. That means we cant yet say whether it works better than whats already available. We also have limited information about how participants themselves felt the drug affected them—most of the reported results come from researchers ratings rather than patient self-reports.
Another study indirectly compared centanafadine with lisdexamfetamine and atomoxetine. It suggested centanafadine may cause less insomnia, anxiety, dry mouth, and appetite loss than lisdexamfetamine. But because the medicines werent tested head-to-head in the same trial, these findings should be interpreted with caution.
Side Effects and Safety
The most common side effects of centanafadine include reduced appetite, insomnia, dry mouth, and headache. These are similar to other ADHD medications. The prescribing information also includes a warning about suicidal thoughts and behaviors—a standard warning for many ADHD and depression medications.
Researchers and the company will continue monitoring the drug as more people use it. Real-world experience often reveals things that clinical trials miss.
What About Anxiety and Depression?
Because centanafadine affects serotonin as well as dopamine and norepinephrine, researchers are curious about whether it could help people who have ADHD alongside anxiety or depression. Early research has shown some promising results, but the full findings of a study looking at ADHD and anxiety havent been published yet.
This is an important area for future research. Many people with ADHD also struggle with anxiety or depression, and finding a medication that addresses multiple conditions could simplify treatment.
The Bottom Line
Centanafadine represents a genuinely new approach to ADHD treatment. Its the first drug in its class to target three brain chemicals, and it offers another option for people who havent found relief with existing medications. But its not a magic bullet. We still dont know how it compares directly to stimulants or other non-stimulants, and its long-term effects will only become clear with time.
If youre considering ADHD medication, the best approach is to talk with your doctor about all your options—old and new. What works for one person may not work for another, and having more choices is ultimately a good thing.
For now, centanafadine is available in the U.S. but not in Australia. If it passes regulatory review there, it could become another tool in the ADHD treatment toolkit. Until then, the conversation around this new drug is just beginning.
This article is based on reporting from The Conversation and Medical Xpress.
Autorius
Mike Brown
Mike Brown – One of those authors who helps readers not get lost in today's news flow. He dives into political affairs as well as world events, social trends, and everyday stories that matter to everyone. The main focus of his work is fact-checking, clear language, and the ability to lay out the key points so that the reader gets a comprehensive and reliable picture of the topic in just a few minutes.
Related Articles
Comments
No comments yet.